Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

by · The Cerbat Gem

Research analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Price Performance

The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.

About Genocea Biosciences

(Get Free Report)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Featured Articles